Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking ethical reflexivity and oversight in health research through an ecosystem approach: A workshop report.

Research ethics·2026
Same author

Shifting power: co-developing a framework for equity in healthcare.

BMC health services research·2026
Same author

Digital health tools and point solutions-pitfalls in population health program measurement.

Frontiers in digital health·2026
Same author

Ankle brachial index not a reliable tool for risk assessment in people with HIV.

HIV medicine·2026
Same author

Building Canada's Health Information Ecosystem Through Equitable Approaches to Public, Patient, and Community Engagement.

Healthcare management forum·2026
Same author

A paradigm shift for health equity in implementation science.

BMC health services research·2026

Related Experiment Video

Updated: Jun 22, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Headache prophylaxis with BoNTA: patient characteristics.

Stephen D Silberstein1, Michael J Marmura, James Shaw

  • 1Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA, USA.

Headache
|June 25, 2009
PubMed
Summary

Botulinum toxin type A (BoNTA) is frequently used for chronic migraine (CM) in specialty headache centers. High disability and frequent headaches characterize patients receiving BoNTA, correlating with treatment utilization.

Related Experiment Videos

Last Updated: Jun 22, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Headache disorders represent a significant global health burden.
  • Botulinum toxin type A (BoNTA) is an established treatment for specific headache types.
  • Understanding patient characteristics is crucial for optimizing BoNTA therapy.

Purpose of the Study:

  • To characterize patients receiving BoNTA for headache disorders.
  • To identify factors associated with BoNTA treatment in headache patients.

Main Methods:

  • Observational, prospective data collection from 703 patients across 10 US headache specialty centers.
  • Data included demographics, headache diagnosis/characteristics, prior treatments, BoNTA response, and Migraine Disability Assessment (MIDAS) scores.
  • Patients maintained daily headache diaries and attended follow-up visits.

Main Results:

  • Most patients (66%) had chronic migraine (CM); 75% reported severe disability (MIDAS grade IV).
  • Over 90% experienced prior prophylactic treatment failure (median of 4 failures).
  • Headache frequency, severity, and prior treatment failures were associated with disability and reduced quality of life.

Conclusions:

  • Patients receiving BoNTA in headache centers predominantly have chronic migraine.
  • Headache disability is significantly correlated with headache frequency and treatment utilization patterns.